Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lancet study a sham?

This article was originally published in The Tan Sheet

Executive Summary

Editors of The Lancet issued an "expression of concern" Jan. 17 about a study published in the journal in October which appeared to be based on "complete fabrication" by the study's lead author. John Sudbo, MD, PhD, Norwegian Radium Hospital, et al., found in a study that long-term use of NSAIDs was linked to reduced incidence of oral cancer but increased risk of death from cardiovascular disease. The hospital alerted Lancet editors to the problem Jan. 13, and the publication states that "the journal has not yet received written confirmation...that fabrication actually took place." The hospital has appointed an investigation committee to look into the matter. Sudbo's findings were first presented at the American Association for Cancer Research annual meeting in April (1"The Tan Sheet" April 25, 2005, p. 10)...

You may also be interested in...

False Lancet study

The Lancet has "received confirmation" that a study published by the journal in October on NSAIDs and reduction of oral cancer contains fabricated data, the publication announces Feb. 4. The false data was provided by lead author John Sudbo, MD/PhD, Norwegian Radium Hospital. The journal's editors released an "expression of concern" about the fabricated data Jan. 17 when they were first alerted to the problem (1"The Tan Sheet" Jan. 23, 2005, In Brief)...

NSAID Use Long-Term May Increase Cardiovascular Death Risk – Study

A small study showing that smokers using NSAIDs are twice as likely to die from cardiovascular causes as smokers who do not use NSAIDs represents another blow to the safety profile of the drug class

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts